A retrospective observational study investigating efficacy of sofosbuvir/ledipasvir therapy without ribavirin in patients with hepatitis C recurrence post liver transplant.
Phase of Trial: Phase IV
Latest Information Update: 24 Oct 2016
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 24 Oct 2016 New trial record
- 14 Sep 2016 Primary endpoint (Sustained virologic response at 12 weeks) has been met, according to results published in the Transplantation.
- 14 Sep 2016 Results published in the Transplantation